This study aims to assess the impact of tirzepatide on clinical outcomes in patients with heart failure, focusing on structural cardiac changes (e.g., left ventricular ejection fraction [LVEF], NT-proBNP levels), functional capacity (6-minute walk test [6MWT]), and patient-reported outcomes (Kansas City Cardiomyopathy Questionnaire [KCCQ] scores). Here, NPPB is linked to cardiomyopathy.